Literature DB >> 25349701

Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS).

Elizabeth R Tang1, Andrew M Schreiner1, Bradley B Pua1.   

Abstract

Due to advances in the understanding of lung adenocarcinoma since the advent of its 2004 World Health System classification, an international multidisciplinary panel [sponsored by the International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS)] has recently updated the classification system for lung adenocarcinoma, the most common histologic type of lung cancer. Here, we summarize and highlight the new criteria and terminology, certain aspects of its clinical relevance and its potential treatment impact, and future avenues of research related to the new system.

Entities:  

Keywords:  Adenocarcinoma; classification; lung neoplasms; pathology; radiology

Year:  2014        PMID: 25349701      PMCID: PMC4209385          DOI: 10.3978/j.issn.2072-1439.2014.09.12

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  78 in total

1.  Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification.

Authors:  Arne Warth; Judith Cortis; Ludger Fink; Annette Fisseler-Eckhoff; Helene Geddert; Thomas Hager; Klaus Junker; Gian Kayser; Julia Kitz; Florian Länger; Alicia Morresi-Hauf; German Ott; Iver Petersen; Albrecht Stenzinger; Alex Soltermann; Saskia Ting; Verena Tischler; Ekkehard Vollmer; Philipp A Schnabel; Wilko Weichert
Journal:  Virchows Arch       Date:  2012-06-23       Impact factor: 4.064

2.  A panel of four immunohistochemical markers (CK7, CK20, TTF-1, and p63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens.

Authors:  Diana Montezuma; Rosa Azevedo; Paula Lopes; Renata Vieira; Ana Luísa Cunha; Rui Henrique
Journal:  Virchows Arch       Date:  2013-10-15       Impact factor: 4.064

3.  Radiographic and pathological analysis of small lung adenocarcinoma using the new IASLC classification.

Authors:  T Honda; T Kondo; S Murakami; H Saito; F Oshita; H Ito; M Tsuboi; H Nakayama; T Yokose; Y Kameda; T Isobe; K Yamada
Journal:  Clin Radiol       Date:  2012-11-10       Impact factor: 2.350

Review 4.  The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group.

Authors:  Erik Thunnissen; Keith M Kerr; Felix J F Herth; Sylvie Lantuejoul; Mauro Papotti; Robert C Rintoul; Giulio Rossi; Birgit G Skov; Birgit Weynand; Lukas Bubendorf; Grünberg Katrien; Leif Johansson; Fernando López-Ríos; Vincent Ninane; Włodzimierz Olszewski; Helmut Popper; Sauleda Jaume; Philipp Schnabel; Luc Thiberville; Florian Laenger
Journal:  Lung Cancer       Date:  2011-12-03       Impact factor: 5.705

5.  A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Kei Suzuki; Stefan S Kachala; Emily C Zabor; Camelia S Sima; Andre L Moreira; Akihiko Yoshizawa; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Mod Pathol       Date:  2012-04-13       Impact factor: 7.842

6.  Subclassification of non-small cell lung cancer by cytologic sampling: a logical approach with selective use of immunocytochemistry.

Authors:  Hillary Z Kimbrell; Karen S Gustafson; Min Huang; Hormoz Ehya
Journal:  Acta Cytol       Date:  2012-07-25       Impact factor: 2.319

7.  Histopathologic characterization of lung adenocarcinoma in relation to fluorine-18-fluorodeoxyglucose uptake on positron emission tomography.

Authors:  Hiromitsu Domen; Yasuhiro Hida; Shozo Okamoto; Kanako C Hatanaka; Yutaka Hatanaka; Kichizo Kaga; Nagara Tamaki; Satoshi Hirano; Yoshihiro Matsuno
Journal:  Jpn J Clin Oncol       Date:  2013-08-02       Impact factor: 3.019

Review 8.  Worldwide trend of increasing primary adenocarcinoma of the lung.

Authors:  Haruhiko Nakamura; Hisashi Saji
Journal:  Surg Today       Date:  2013-06-11       Impact factor: 2.549

9.  F18-FDG PET-CT analyses of small peripheral adenocarcinoma of the lung.

Authors:  Yoshiyuki Takahashi; Shodayu Takashima; Shinichiro Watanabe; Yasuhiko Tomita; Tomoaki Hakucho; Chie Miyake; Daisuke Morimoto; Takuya Hosoki; Katsuyuki Nakanishi; Masahiko Higashiyama
Journal:  Acta Radiol       Date:  2012-11-08       Impact factor: 1.990

10.  Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations.

Authors:  Xing-Ya Li; Yan-Qiu Zhao; Rui-Qing Liu; Jian-Bo Zhang; Jie Ma; Li-Juan Chen; Xiu-Feng Hu
Journal:  Pathol Res Pract       Date:  2013-12-05       Impact factor: 3.250

View more
  28 in total

Review 1.  [The new TNM classification for lung tumors : Changes and the assessment of multiple tumor foci].

Authors:  A Harms; M Kriegsmann; L Fink; F Länger; A Warth
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

2.  Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer.

Authors:  Wentao Li; Jichen Qu; Zhifei Xu
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

3.  Advances in lung cancer with a focus on ATS 2016 updates.

Authors:  Jinghong Li; Mark M Fuster
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

4.  Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer.

Authors:  Fei Liu; Liang Hu; Yuefan Ma; Bingyu Huang; Zihan Xiu; Peihua Zhang; Keyuan Zhou; Xudong Tang
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

5.  The expression of SALL4 is significantly associated with EGFR, but not KRAS or EML4-ALK mutations in lung cancer.

Authors:  Xiangbo Jia; Rulin Qian; Binbin Zhang; Song Zhao
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

6.  Development and Validation of a Risk Stratification Model of Pulmonary Ground-Glass Nodules Based on Complementary Lung-RADS 1.1 and Deep Learning Scores.

Authors:  Qingcheng Meng; Bing Li; Pengrui Gao; Wentao Liu; Peijin Zhou; Jia Ding; Jiaqi Zhang; Hong Ge
Journal:  Front Public Health       Date:  2022-05-23

7.  Combined Radiomic and Visual Assessment for Improved Detection of Lung Adenocarcinoma Invasiveness on Computed Tomography Scans: A Multi-Institutional Study.

Authors:  Pranjal Vaidya; Kaustav Bera; Philip A Linden; Amit Gupta; Prabhakar Shantha Rajiah; David R Jones; Matthew Bott; Harvey Pass; Robert Gilkeson; Frank Jacono; Kevin Li-Chun Hsieh; Gong-Yau Lan; Vamsidhar Velcheti; Anant Madabhushi
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

8.  2020 Innovation-Based Optimism for Lung Cancer Outcomes.

Authors:  Erin L Schenk; Tejas Patil; Jose Pacheco; Paul A Bunn
Journal:  Oncologist       Date:  2020-12-20

9.  Effect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study.

Authors:  Seok Whan Moon; Si Young Choi; Mi Hyoung Moon
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

10.  Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases.

Authors:  Mark Kriegsmann; Thomas Muley; Alexander Harms; Luca Tavernar; Torsten Goldmann; Hendrik Dienemann; Esther Herpel; Arne Warth
Journal:  Diagn Pathol       Date:  2015-12-08       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.